Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits.

BACKGROUND: Some patients with untreated coeliac disease are negative for serum endomysial autoantibodies (EmA) targeted against transglutaminase 2 (TG2). AIMS: To evaluate the clinical and histological features of EmA-negative coeliac disease, and to examine whether EmA-equivalent autoantibodies against TG2 can be seen in the small-bowel mucosa when absent in serum. PATIENTS: Serum EmA was studied in 177 biopsy-proved specimens from adult patients with coeliac disease. 20 patients with intestinal diseases served as non-coeliac controls; three had autoimmune enteropathy with villous atrophy. METHODS: Clinical manifestations, small-bowel mucosal morphology, intraepithelial inflammation and TG2-specific extracellular immunoglobulin A (IgA) deposits were investigated in both serum EmA-negative and EmA-positive patients. RESULTS: 22 patients with IgA-competent coeliac disease were negative for serum EmA. Three of these had small-bowel lymphoma. Patients with EmA-negative coeliac disease were older, had abdominal symptoms more often, and the density of gammadelta+ intraepithelial lymphocytes in their intestinal mucosa was lower than in EmA-positive patients; otherwise the histology was similar. All serum EmA-negative patients with coeliac disease, but none of the disease controls, had gluten-dependent mucosal IgA deposits alongside TG2 in the small-bowel mucosal specimens. In vivo deposited IgA was shown to be TG2-specific by its ability to bind recombinant TG2. CONCLUSIONS: Negative serum EmA might be associated with advanced coeliac disease. TG2-targeted autoantibodies were deposited in the small-bowel mucosa even when absent in serum. This finding can be used in the diagnosis of seronegative coeliac disease when the histology is equivocal. It may also be helpful in the differential diagnosis between autoimmune enteropathy and coeliac disease.

Coeliac disease case finding and diet monitoring by point-of-care testing.

BACKGROUND: Immunoglobulin A class transglutaminase autoantibodies are highly predictive markers of active coeliac disease, a disorder difficult to recognize solely on clinical grounds. AIMS: To develop and evaluate a simple rapid test for point-of-care detection of coeliac autoantibodies. METHODS: The novel whole blood test utilizes the patient's endogenous transglutaminase in red blood cells for detection of transglutaminase-specific immunoglobulin A antibodies present in the blood sample, with normal plasma immunoglobulin A detection as positive test control. We evaluated 284 patients under suspicion of coeliac disease and undergoing jejunal biopsy, and 263 coeliac patients on a gluten-free diet, 383 being tested prospectively in a point-of-care setting. Results were compared with histology, conventional serum autoantibody results and dietary adherence. RESULTS: The rapid test showed 97% sensitivity and 97% specificity for untreated coeliac disease, and identified all immunoglobulin A-deficient samples. Point-of-care testing found new coeliac cases as efficiently as antibody tests in laboratory. Coeliac autoantibodies were detected onsite in 21% of treated patients, while endomysial and transglutaminase antibodies were positive in 20% and 19%, respectively. The positivity rate correlated with dietary lapses and decreased on intensified dietary advice given upon positive point-of-care test results. CONCLUSIONS: Point-of-care testing was accurate in finding new coeliac cases and helped to identify and decrease dietary non-compliance.

Synthesis and complexation properties of DTPA-N,N''-bis[bis(n-butyl)]-N'-methyl-tris(amide). Kinetic stability and water exchange of its Gd3+ complex.

A novel DTPA-tris(amide) derivative ligand, DTPA-N,N''-bis[bis(n-butyl)]-N'-methyl-tris(amide)(H2L3) was synthesized. With Gd3+, it forms a positively charged [Gd(L3)]+ complex, whereas with Cu2+ and Zn2+ [ML3], [MHL3]+ and [M2L3]2+ species are formed. The protonation constants of H2L3 and the stability constants of the complexes were determined by pH potentiometry. The stability constants are lower than those for DTPA-N,N''-bis[bis(n-butyl)amide)](H3L2), due to the lower negative charge and reduced basicity of the amine nitrogens in (L3)2-. The kinetic stability of [Gd(L3)]+ was characterised by the rates of metal exchange reactions with Eu3+, Cu2+ and Zn2+. The exchange reactions, which occur via proton and metal ion assisted dissociation of [Gd(L3)]+, are significantly slower than for [Gd(DTPA)]2-, since the amide groups cannot be protonated and interact only weakly with the attacking metal ions. The relaxivities of [Gd(L2)] and [Gd(L3)]+ are constant between 10-20 degrees C, indicating a relatively slow water exchange. Above 25 degrees C, the relaxivities decrease, similarly to other Gd3+ DTPA-bis(amide) complexes. The pH dependence of the relaxivities for [Gd(L3)]+ shows a minimum at pH approximately 9, thus differs from the behaviour of Gd3+-DTPA-bis(amides) which have constant relaxivities at pH 3-8 and an increase below and above. The water exchange rates for [Gd(L2)(H2O)] and [Gd(L3)(H2O)]+, determined from a variable temperature (17)O NMR study, are lower than that for [Gd(DTPA)(H2O)]2-. This is a consequence of the lower negative charge and decreased steric crowding at the water binding site in amides as compared to carboxylate analogues. Substitution of the third acetate of DTPA5- with an amide, however, results in a less pronounced decrease in kex than substitution of the first two acetates. The activation volumes derived from a variable pressure (17)O NMR study prove a dissociative interchange and a limiting dissociative mechanism for [Gd(L2)(H2O)] and [Gd(L3)(H2O)]+, respectively.

In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies.

BACKGROUND: IgA class serum autoantibodies against type 2 (tissue) transglutaminase (TG2) bind to both intestinal and extraintestinal normal tissue sections in vitro, eliciting endomysial, reticulin, and jejunal antibody reactions. It is not known whether similar binding also occurs in coeliac patients in vivo, and may thereby contribute to disease manifestations. AIMS: To investigate intestinal and extraintestinal coeliac tissues for the presence of in vivo bound TG2 specific IgA and its relation to small intestinal mucosal atrophy. PATIENTS: We investigated jejunal samples with normal villous morphology from 10 patients with developing coeliac disease who subsequently progressed to a flat lesion, from 11 patients with dermatitis herpetiformis, and from 12 non-coeliac controls. Six extrajejunal biopsy samples (liver, lymph node, muscle, appendix), obtained based on independent clinical indications from patients with active coeliac disease, were also studied. METHODS: Double colour immunofluorescent studies for in situ IgA, TG2, and laminin were performed. IgA was eluted from tissue sections and tested for TG2 specificity by enzyme linked immunosorbent assay and indirect immunofluorescence. RESULTS: IgA (in one IgA deficient case IgG) deposition on extracellularly located TG2 was detected in jejunal and extrajejunal specimens of all coeliac patients, and also in seven of 11 dermatitis herpetiformis patients, of whom two had no circulating endomysial antibodies. IgA eluted from extraintestinal coeliac tissues was targeted against TG2. CONCLUSIONS: Coeliac IgA targets jejunal TG2 early in disease development even when endomysial antibodies are not present in the circulation. Extraintestinal target sites of coeliac IgA further indicate that humoral immunity may have a pathogenetic role.

[Complexation properties of the ligand EOB-DTPA and the kinetic stability of Gd(EOB-DTPA)]. / Az EOB-DTPA ligandum komplexképzó sajátságai és a Gd(EOB-DTPA)2- kinetikai stabilitása.

Due to the presence of the ethoxy-benzyl group, the lipophilicity of the complex Gd(EOB-DTPA)2- is higher than that of Gd(DTPA)2- and thus Gd(EOB-DTPA)2- can be used as a liver specific contrast agent in Magnetic Resonance Imaging. The stability constants of the complexes of Fe2+, Fe3+, Zn2+ and Cu2+ formed with EOB-DTPA practically agree with those of the respective DTPA complexes. The complexes of EOB-DTPA formed with larger metal ions, like Ca2+, Ba2+, Gd3+ and other lanthanides, exhibit larger stability constants than the complexes of DTPA by 0.5-1 logK unit. The stability constants of the complexes Ln(EOB-DTPA)2- increase with increasing atomic number till the middle of the series. For the elements Tb to Ho the logKLnL values are approximately equal and a weak decrease can be observed for the heaviest elements, probably because of steric hindrance between the functional groups. The exchange reactions between the complex Gd(EOB-DTPA)2- and Y3+ ions occur predominantly through the formation and rate determining dissociation of the mono- and diprotonated complexes. The rate constants characterizing these reaction pathways are lower by a factor of three than the respective rate constants, known for the dissociation of Gd(DTPA)2-. On the basis of its higher kinetic stability, Gd(EOB-DTPA)2- can be used for in vivo investigations in medical diagnosis.

Stability constants and 1H relaxation effects of ternary complexes formed between Gd-DTPA, Gd-DTPA-BMA, Gd-DOTA, and Gd-EDTA and citrate, phosphate, and carbonate ions.

Formation of ternary complexes between Gd-DTPA, Gd-DTPA-BMA, and Gd-DOTA, used as contrast enhancement agents in MRI and the endogenously available carbonate and phosphate ions, has been demonstrated. The extent of ternary complex formation and its effect on the proton relaxation, measured at 9 MHz, rates is negligible at around pH < 8. The complex Gd-EDTA forms more stable ternary complexes with carbonate and phosphate and it also strongly coordinates the terdentate citrate ligand. The formation of ternary complexes Gd-EDTA(X) (X = CO3(2-), Cit3-) results in a significant decrease in the proton relaxation rates under physiological conditions.

Anatomic fitting studies of a total artificial heart in heart transplant recipients. Critical dimensions and prediction of fit.

Anatomic fitting studies of the Cleveland Clinic-Nimbus total artificial heart were performed in 33 patients undergoing heart transplantation. The pump fit in the pericardial space in 20 men (80%) and 4 women (50%). There was no significant difference between the Fit and Non-Fit groups in external chest dimensions. Among 42 intrathoracic dimensions, the distance from the center of the mitral valve to the diaphragm (Fit: 5.6 +/- 2.2 cm, Non-Fit: 3.6 +/- 0.4 cm, p < 0.00001) and the distance from the caudal end of the pulmonary valve to the diaphragm (Fit: 9.4 +/- 1.6 cm, Non-Fit: 6.3 +/- 0.8 cm, p < 0.0001) were the most critical. To predict anatomic fit, an index (A x B x C) was obtained from chest X-ray measurements (A, the craniocaudal distance from the dorsal region of the 8th left rib to the left diaphragm; B, the maximum left chest width; and C, the maximum anteroposterior sternum-vertebrae dimension). The pump fit in 88.5% of the patients with an index above 1200 cm3, whereas it fit in only 14.3% of the patients with an index below 1200 cm3 (p < 0.001). This index was an easily obtainable, good predictor of anatomic fit.

In vitro evaluation of automatic control performance of a total artificial heart with changes in pump orientation.

Unlike in animal experiments, the pump orientation of a total artificial heart (TAH) can change remarkably in humans with the recipient's posture (upright, supine, or prone), thus affecting its filling characteristics. The left master alternate control mode of the Cleveland Clinic-Nimbus (CC-N) TAH adjusts beat rate by maintaining the left pump at 90% filling, producing a Frank-Starling like preload sensitivity. In order to verify that the CC-N TAH functions properly regardless of the gravity effects on pump filling, the preload sensitivity curves of the CC-N TAH were evaluated on a mock circulatory loop with the simulated supine (right pump up) and prone (left pump up) positions in humans. The right preload sensitivity was slightly higher when the right pump was up versus down, and likewise the left preload sensitivity was higher when the left pump was up versus down. Despite these gravity effects on pump filling, right and left preload sensitivity remained within physiologic range and the automatic control of the CC-N TAH functioned properly without significant postural effects.

The Cleveland Clinic-Nimbus total artificial heart. Design and in vitro function.

We describe the design and in vitro testing of the Cleveland Clinic-Nimbus electrohydraulic permanent total artificial heart as it nears completion of development. The total artificial heart uses an electric motor and hydraulic actuator to drive two diaphragm-type blood pumps. The interventricular space contains the pump control electronics and is vented to an air-filled compliance chamber. Pericardial tissue valves and biolized blood-contacting surfaces potentially eliminate the need for anticoagulation. In vitro studies on a mock circulatory circuit demonstrated preload-sensitive control of pump output over the operating range of the blood pump: 70 to 160 beats/min and 5 to 9.6 L/min at right and left atrial pressures of 1.0 to 7.0 mm Hg and 5.0 to 12.0 mm Hg, respectively. The pump output was found to be insensitive to afterload over a range of 15 to 40 mm Hg mean pulmonary artery pressure and 60 to 130 mm Hg mean systemic pressure. The left master alternate control mode balanced the ventricular outputs during simulated bronchial artery shunting of up to 20% of cardiac output. A 10% to 15% right-pump, stroke-volume limiter balanced ventricular outputs during maximum output of 9.6 L/min. In response to a sustained increase in systemic venous return, the pump increased output by 2 L/min (29%) in 35 seconds. Thus the Cleveland Clinic-Nimbus total artificial heart meets the National Heart, Lung, and Blood Institute hemodynamic performance goals for devices being developed for permanent heart replacement. The biolized blood-contacting surfaces should decrease the risk of thromboembolism associated with circulatory assist devices.

Continuing development of the Cleveland Clinic-Nimbus total artificial heart.

A completely implanted total artificial heart (TAH) is under development by Nimbus, Inc., and the Cleveland Clinic Foundation (CCF). Key features of the system include an electrohydraulic energy converter, an automatic control system that produces a Frank-Starling response, and dual ventricles composed of graphite-epoxy and titanium with gelatin blood contacting surfaces. The system is controlled by a single substrate, hybridized microcircuit (the hybrid). Fabrication of the TAH control hybrid has recently been completed and testing begun. Its design emphasizes simplicity, reliability, and efficiency. Particular attention was given to optimizing thermal management. Externally controlled TAH systems have been used in eight in vivo experiments of up to 120 days' duration. In the last two of these experiments, a variable volume device was also implanted with excellent results. In vivo use of the system has demonstrated the Frank-Starling pump response, but the systems quickly reach maximum output with the bovine animal models. Human fitting studies, including adult patients undergoing heart transplantation, demonstrated satisfactory fit of the pump within the pericardium without compression of the vascular structures or chest wall. Measurements of chest circumference, plain chest films, and transesophageal echocardiograms should provide reliable predictions of pump fit in the majority of patients.

Hemodynamic changes with posture in calves with total artificial heart.

Hemodynamic changes with posture, sitting versus standing, were analyzed in five Holstein calves with the Cleveland Clinic-Nimbus TAH. This total artificial heart (TAH) has a left master alternate control mode that adjusts the pump rate and consequently pump flow proportional to the pulmonary venous return to the left pump (AUTO period). However, in this series of experiments, the pump reached its maximum beat rate within 1-5 days post operatively, after which pump flow could not increase (MAX period). Hemodynamic parameters (RAP, LAP, PAP, AoP, and pump flow) were obtained every 15-20 min throughout the experiments for as long as 120 days and averaged for each posture for each period. During the AUTO period, the flow while standing was significantly higher than that while sitting (standing: 8.7 +/- 0.2 L/min; sitting: 7.5 +/- 0.4 L/min; p < 0.05), and the systemic vascular resistance (SVR) was significantly lower (standing: 895 +/- 93 dyne.sec.m-5; sitting: 1,041 +/- 124 dyne.sec.m-5; p < 0.05). During the MAX period, the AoP and SVR standing were significantly lower than those sitting (AoP standing: 91 +/- 7 mmHg; AoP sitting: 98 +/- 7 mmHg; p < 0.05; SVR standing: 652 +/- 75 mmHg; SVR sitting: 730 +/- 96 mmHg; p < 0.05). The Cleveland Clinic-Nimbus TAH responded well to these changes in position, increasing pump flow and maintaining the AoP during the AUTO period.

Effects of a total artificial heart right stroke volume limiter on left-right hemodynamic balance.

In a completely implantable total artificial heart (TAH), the left-right flow difference attributable to higher volumetric efficiency of the right pump and bronchial artery shunting has always been a significant problem. The automatic control of the Cleveland Clinic-Nimbus TAH accommodates for the left-right flow difference when the beat rate is below maximum (AUTO range). However, at its maximum beat rate (MAX), high left atrial pressure (LAP) (greater than 25 mmHg) with relatively low right atrial pressure (RAP) (less than 8 mmHg) were observed both in vitro and in vivo, suggesting the need for a stroke volume limiter (SVL) of the right pump. In vitro volume loading tests showed 10%, 15%, and 20% SVLs prevented a disproportionate increase of LAP. In vivo studies in five Holstein calves also showed a balanced LAP-RAP relationship with 10% and 15% SVLs at MAX. The left pump flow was not affected by this range of SVLs either in vitro or in vivo. Pulmonary function was maintained with either size SVL, with autopsies revealing absence of pulmonary congestion and minimal pleural effusions in two calves surviving for more than 1 month. Although additional studies are needed to determine the appropriate size of the SVL, both 10% and 15% SVLs were effective in maintaining left-right hemodynamic balance in this TAH.

Effects of mechanical ventilation and spontaneous respiration on hemodynamics in calves with total artificial hearts.

The effects of respiration on hemodynamics were evaluated in four Holstein calves with total artificial hearts (TAH). The electrohydraulic actuated E4T-TAH has a continuously reciprocating actuator packaged between two alternately ejecting blood pumps that passively fill. The hemodynamic parameters (right atrial pressure [RAP], left atrial pressure [LAP], pulmonary artery pressure [PAP], aortic pressure [AoP]), and right and left pump filling (Rt% fill and Lt% fill) were measured when the animal was intubated and mechanically ventilated. These measurements were repeated with spontaneous respiration after the animal was extubated. With mechanical ventilation, LAP, PAP, and AoP were significantly higher during inspiration than during expiration. However, RAP during inspiration was slightly lower than that during expiration. The Rt% fill during inspiration was significantly lower than during expiration, but Lt% fill during inspiration was significantly higher than during expiration. During spontaneous respiration, these changes were opposite to those observed during mechanical ventilation. That mechanical ventilation generates positive intrathoracic pressure during inspiration, but spontaneous respiration generates negative pressure may explain these results. The change in venous return to the right atrium caused the change in RAP to be opposite in direction to that of the other pressures.

Initial in vivo tests of an electrohydraulic actuated total artificial heart.

The authors are involved in developing a total artificial heart (TAH) for permanent human use. This device was designed to fit human anatomy, and it has housings made of carbon fiber-epoxy composite and titanium. Tissue valves and protein coating of blood contacting surfaces minimize the need for anticoagulants. A continuously reciprocating electrohydraulic actuator is packaged between two alternately ejecting and passively filling ventricles. The control system varies the pump rate to maintain average left ventricular filling at 90%. This TAH in vivo successively progressed through 1, 5, 9, and 45 day implants in calves of 84, 94, 82, and 82 kg preoperative body weights. The operating modes include automatic and fixed rate. The chronic and acute effects of varying the right pump displaced stroke volume indicated the need for it to be limited to 85% of that of the left for stable hemodynamics at maximum flow. The pump exhibited afterload insensitive and preload sensitive performance. Pump output ranged from 4.0-9.5 L/min at left atrial pressures of 7-16 mmHg at pump rates of 80-160 beats/min in these four experiments. These data suggest that this device will meet clinical hemodynamic requirements; it has the potential for total implantable cardiac replacement.

Anatomic study for in vivo evaluation of a total artificial heart in calves.

A poor fit will negate any physiologic evaluation of an implantable total artificial heart (TAH). Fifteen Holstein calves (weight, 65-111 kg) were used to measure intrathoracic dimensions for TAH design, to find correlations between intrathoracic and external parameters for preoperative animal selection, and to suggest minor modifications for fitting a TAH in calf chests. The following dimensions were found to be critical to avoid compromising venous return: 1) mitral annulus center (MVC)-sternum, 10.4 +/- 1.0 cm; 2) tricuspid annulus center (TVC)-sternum, 9.8 +/- 1.6 cm; 3) MVC-TVC, 5.5 +/- 0.4 cm; 4) MVC-diaphragm, 3.4 +/- 0.8 cm; 5) MVC-left chest wall, 4.5 +/- 0.9 cm; and 6) TVC-right chest wall, 4.5 +/- 1.0 cm. These dimensions had no statistically significant correlation with body weight, but three of them did with the following external parameters: 1) bronchial carina-sternum on chest radiograph, p less than 0.05; 2) dorsoventral dimension at xiphoid, p less than 0.05; and 3) circumference at the caudal end of the scapula, p less than 0.05. Based on these results, the port orientation of the left housing of this electrohydraulic TAH designed for humans was modified for in vivo evaluation in calves. No other pump features required change. These data should prove useful to others involved in TAH development.

Development of the E4T electrohydraulic total artificial heart.

A completely implantable total artificial heart (TAH) is being developed based on many years of research performed at the Cleveland Clinic Foundation and Nimbus, Inc. The pumping unit consists of biolized surface-treated pusher plate blood pumps powered by an interventricular electrohydraulic energy converter. A variable volume device references the back side of the pusher plates to lung pressure. Electrical power is supplied by a transcutaneous energy transmission system, integrated with a wearable external battery pack. An implanted internal battery provides back-up power. System design and optimization efforts have resulted in a compact pumping unit package and an overall TAH that meets anatomic, physiologic, and engineering requirements. Overall pumping unit basic dimensions are 98 mm diameter and 80 mm thick. The blood pumps have a truncated conical shape and are separated by a thin interventricular septum 21 mm thick. Theoretical stroke volume is 64 ml, and maximum stroke length is 13.2 mm. Normal pump operation is at 90% of full stroke, which yields a net output of 53 ml, with valve regurgitation taken into account.

An intrathoracic left ventricular assist system: utilization of results from a development program.

An intrathoracic, electrohydraulically actuated, left ventricular assist system (LVAS) was subjected to formal device readiness testing. Endurance testing was initiated on eight systems before testing was halted due to failure of four of the systems. Three failed due to environmental leakage. Solutions were straightforward, involving gasket changes and o-ring resizing. The fourth failure involved a magnetic coupling piston swelling and seizing. The failure was attributed, after long investigation, to hydrogen adsorption by the samarium-cobalt magnets. An unknown number of coupling magnets were affected in this fashion, necessitating complete replacement of magnets to resolve the problem. However, this was beyond the scope of the program, and no further endurance testing was accomplished. The test experience of the Nimbus/CCF LVAS has demonstrated all functional aspects of the complete LVAS, both in vitro and in vivo, and the endurance and reliability potential is indicated as well. Although the LVAS program is currently inactive, its legacy of technical innovations continue to drive the development of other medical devices.

Long-term in vivo study of gas diffusion in bilaminar compliance chambers.

The problem of gas diffusion from compliance chambers in long-term pulsatile blood pump implantation continues. To evaluate and predict gas diffusion at the intrathoracic tissue interface, eight air-filled static bilaminar compliance chambers were implanted in four calves for a mean duration of 191 days. Mean volume loss was 40.3 +/- 6.2 ml (0.2 ml/day) compared with previous results of 1.2 ml/day for pure Hexsyn diaphragms. The residual gas in the chamber was analyzed as nitrogen = 89.6 +/- 0.6%; oxygen = 1.5 +/- 1.1%; and carbon dioxide = 8.8 +/- 0.6%. The resulting gas composition is assumed equivalent to that of the tissue interface and was used in developing a diffusion model. For a complete left ventricular assist system (LVAS), gas diffusion at the arterial blood and tissue interface was simulated. The predicted time to reach a minimum volume of 90 ml (compliance volume equal to full pump stroke volume) was in excess of 1 year.

A simple and compact total artificial heart for temporary use.

Thromboembolism and anatomic fit are the major issues to be addressed in the design of a heart replacement device for total circulatory support. In an attempt to overcome these problems, a simple 70 mm3 displacement pusher plate, low pressure, pneumatically driven TAH was developed for temporary use. For optimal anatomic fit, easy implantation, and better flow patterns, the 5.7 X 10.7 cm total artificial heart (1) TAH was made of two essentially flat pumps integrated into a single unit. This single package approach avoids the dead space that occurs between the two pieces of conventional TAH and thus minimizes overall volume. It was designed to be positioned in the pericardial sac in a fashion similar to the natural ventricles and, based upon previous anatomic studies, fit in the average sized adult patient. In contrast to conventional free diaphragm pumps, the diaphragms of this TAH are supported by pusher plates that have a unique guide mechanism at the center to ensure a linear-controlled diaphragm motion and consequent uniform blood flow distribution. The guide of each pusher plate nests into the other, resulting in minimal thickness of the package. By using a simple displacement transducer, reliable output monitoring, with the possibility of selection of various pumping modes and adjustment of stroke volume, is possible. The authors anticipate this efficient and practical TAH to be a suitable temporary heart replacement device.

A biolized implantable ventricular assist device compatible with IABP console.

A low pressure pneumatic pusher plate blood pump was developed for temporary right, left, or biventricular assist. Important features of this pump are its 1) driveability by the standard, easily available intraaortic balloon pump (IABP) console; 2) gelatin coated internal surface for blood compatibility; 3) essentially flat disc shape, 3 cm thick and 11 cm in diameter, for optimal anatomic fit; and 4) unique pusher plate guide mechanism to ensure linear motion without deflections of the diaphragm, and consequent uniform flow distribution into the pump. The guide telescopes into itself to avoid a housing protrusion for easy implantability; this controlled movement also provides a number of performance, control, and diagnostic benefits. The pump's 60 ml displacement gives up to 4.7 L/min at 80 bpm and 6.7 L/min at 120 bpm outputs in a mock loop. This VAD has been implanted in two calves for 43 to 84 days, continuously driven by a Datascope IABP console. An average 5 L/min pump output has been observed in both synchronous and fixed rate modes. No anticoagulation was required. We expect extensive clinical use of this VAD, based on its reliability, low cost, and simplicity.